Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04460859
Other study ID # 2027
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 9, 2020
Est. completion date June 2022

Study information

Verified date September 2021
Source Unity Health Toronto
Contact Laurent Brochard, MD
Phone 416-864-5686
Email Laurent.Brochard@unityhealth.to
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The RECRUIT study is a multinational, multicenter physiological observational study conducted by the PLUG working group. It is a single-day study (1.5-2 hours) associated with specific lung (de)recruitment maneuvers to verify the feasibility of measuring the potential for lung recruitment in mechanically ventilated patients with ARDS by electrical impedance tomography (EIT).


Description:

Despite higher positive end-expiratory pressure (PEEP) being associated with multiple physiologic benefits, randomized clinical trials comparing higher vs. lower PEEP levels failed to show improved survival of ARDS patients. Higher PEEP should fully exploit its benefits only when implemented in patients with higher potential for alveolar recruitment (i.e., the decrease of non-aerated lung tissue at higher airway pressure) or in patients with airway closure. Retrospective analysis of randomised clinical trials with PEEP suggests that when high PEEP is used in responders (oxygenation), survival may be better. Conversely, in the absence of significant recruitment, higher PEEP should be avoided and lower PEEP might be recommended. Titration of PEEP provided by the mechanical ventilator in patients with severe lung injury should thus be based on bedside information on lung recruitability. However, no valid method exists to define the best PEEP to optimize recruitment and minimize lung overdistention. Recruitability varies and is often not assessed. Electrical impedance tomography (EIT) is a non-invasive bedside imaging technique for measuring the potential for lung recruitment in ARDS patients. By performing lung (de)recruitment maneuvers and in-depth analyses, we will define lung recruitability indices and develop methods for real-time and personalized PEEP selection. This study will prove the feasibility of minimizing risks associated with inadequate mechanical ventilation by EIT.


Recruitment information / eligibility

Status Recruiting
Enrollment 171
Est. completion date June 2022
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Intubated moderate and severe ARDS according to the Berlin definition (PaO2/FiO2 ratio <= 200 mmHg) - Under continuous sedation with or without paralysis Exclusion Criteria: - Age <18 years - Bronchopleural fistula - Pure COPD exacerbation - Contraindication to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode belt placement) - Hemodynamic instability (Systolic BP < 75 mmHg or MAP < 60 mmHg despite vasopressors and/or heart rate < 55 bpm) - Attending physician deems the transient application of high airway pressures to be unsafe

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Specific lung recruitment maneuvers
Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.

Locations

Country Name City State
Brazil Faculdade de Medicina da University São Paulo São Paulo
Canada St. Michael's Hospital Toronto Ontario
Italy Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan
Spain Vall d'Hebron University Hospital Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Unity Health Toronto

Countries where clinical trial is conducted

Brazil,  Canada,  Italy,  Spain, 

References & Publications (3)

Chen L, Del Sorbo L, Grieco DL, Junhasavasdikul D, Rittayamai N, Soliman I, Sklar MC, Rauseo M, Ferguson ND, Fan E, Richard JM, Brochard L. Potential for Lung Recruitment Estimated by the Recruitment-to-Inflation Ratio in Acute Respiratory Distress Syndrome. A Clinical Trial. Am J Respir Crit Care Med. 2020 Jan 15;201(2):178-187. doi: 10.1164/rccm.201902-0334OC. — View Citation

Costa EL, Borges JB, Melo A, Suarez-Sipmann F, Toufen C Jr, Bohm SH, Amato MB. Bedside estimation of recruitable alveolar collapse and hyperdistension by electrical impedance tomography. Intensive Care Med. 2009 Jun;35(6):1132-7. doi: 10.1007/s00134-009-1447-y. Epub 2009 Mar 3. — View Citation

Frerichs I, Amato MB, van Kaam AH, Tingay DG, Zhao Z, Grychtol B, Bodenstein M, Gagnon H, Böhm SH, Teschner E, Stenqvist O, Mauri T, Torsani V, Camporota L, Schibler A, Wolf GK, Gommers D, Leonhardt S, Adler A; TREND study group. Chest electrical impedance tomography examination, data analysis, terminology, clinical use and recommendations: consensus statement of the TRanslational EIT developmeNt stuDy group. Thorax. 2017 Jan;72(1):83-93. doi: 10.1136/thoraxjnl-2016-208357. Epub 2016 Sep 5. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Potential for lung recruitment The potential for lung recruitment will be assessed with EIT. Several methods will be used and compared, based on e.g. pixel information of lung aeration, and pressure-volume characteristics at different PEEP steps. 2 hours
Secondary Recruitment-to-inflation (R/I) ratio 2 hours
Secondary EIT-based optimum PEEP level 2 hours
Secondary PEEP level resulting in end-expiratory transpulmonary pressure between 0 and 2 cmH2O For those patients with esophageal pressure measurements available 2 hours
Secondary Organ dysfunction as per the sequential organ failure assessment (SOFA) score SOFA score min-max: 0-24; a higher score is associated with poor prognosis. Day 1, 3, 7
Secondary Vital status at ICU discharge, 28 days, and hospital discharge Vital status (death/alive) will be assessed via chart review Through study completion, up to 1 year
Secondary Ventilator free days Day 28
See also
  Status Clinical Trial Phase
Completed NCT03909854 - Pragmatic Investigation of Volume Targeted Ventilation-1 N/A
Recruiting NCT02637011 - Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life N/A
Completed NCT02288949 - Stratification of the Acute Respiratory Distress Syndrome
Recruiting NCT02574169 - Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation N/A
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Terminated NCT04511650 - Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 Phase 2
Completed NCT05024500 - Clinical and Functional Outcomes of Critically Ill Patients With COVID-19 N/A
Recruiting NCT01339533 - Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation Phase 2
Active, not recruiting NCT01274260 - Trial of Steroids in Pediatric Acute Lung Injury/ARDS Phase 2
Recruiting NCT03296059 - Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates N/A
Recruiting NCT04609865 - Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia Phase 3
Active, not recruiting NCT04009330 - Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
Not yet recruiting NCT05847517 - Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) Phase 3
Not yet recruiting NCT06127381 - An Open-label Study of the Safety and Pharmacokinetics of the TGKP Phase 1
Completed NCT01854424 - Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS N/A
Completed NCT03870009 - Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS N/A
Completed NCT04311697 - Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Phase 2/Phase 3
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Completed NCT01926093 - Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients N/A
Terminated NCT01506401 - The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial Phase 3